Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure.

Autor: Munakata, Mamoru, Ono, Yuichi, Koyama, Masayuki, Fukui, Kozo, Satoh, Kei, Suzuki, Sohei
Zdroj: Japanese Journal of Thoracic & Cardiovascular Surgery; 2000, Vol. 48 Issue 2, p106-111, 6p
Abstrakt: Objective: The enhanced generation of various chemical mediators is regarded as one of the mechanisms by which severe heart failure progresses to multiple organ failure. Platelet-activating factor is a phospholipid mediator which plays an important role in inflammatory reactions and circulatory shock. We studied the changes in platelet-activating factor levels in a canine heart failure model treated with a left ventricular assist device and hemofiltration, and assessed the effect of a protease inhibitor, nafamostat mesilate. Methods: Twenty dogs underwent multiple coronary ligations, and at 2 hours after the ligations they were maintained on left ventricular assist device support with continuous hemofiltration. The animals were divided into two groups: a nafamostat group (n = 10) that received nafamostat mesilate (2 mg/kg/hr), and a control group (n = 10) that received vehicle only. Results: The blood platelet-activating factor level, before coronary ligations, in the control and nafamostat groups was 2.3 ± 0.4 and 2.0 ± 0.7 ng/ml, respectively, and the coronary ligations had little effect on the platelet-activating factor. However, after the initiation of left ventricular assist device, the platelet-activating factor in the control group (5.6 ± 2.2) was significantly higher (p < 0.05) than that in the nafamostat group (1.1 ± 0.3). Nafamostat administration was also effective in controlling the increase in the blood lactate level. Hemofiltration did not change the platelet-activating factor. Conclusions: We concluded that platelet-activating factor may play a critical role in the development of severe heart failure with left ventricular assistance, and nafamostat administration is likely to be beneficial in such a critical condition by suppressing the platelet-activating factor level. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index